CLL patients' clinical characteristics
| CLL patient label . | Sex . | Age at study, y . | Binet stage . | IgVH status . | IgVH gene . | ZAP-70, % . | CD38, % . | FISH analysis . |
|---|---|---|---|---|---|---|---|---|
| CLL-1 | F | 59 | B | Unmutated | 3-33 | 90 | 3 | Negative |
| CLL-2 | M | 59 | A | Unmutated | 1-69 | 65 | 76 | del13q, del11q |
| CLL-3 | M | 45 | A | Unmutated | 3-09 | 74 | 0 | NE |
| CLL-4 | M | 49 | B | Unmutated | 1-69 | 76 | 1 | del11q |
| CLL-5 | M | 59 | B | Unmutated | 3-73 | 10 | 8 | del13q, del14q, del6q |
| CLL-6 | F | 45 | A | Mutated | 4-34 | 0 | 1 | del13q |
| CLL-7 | F | 41 | B | Mutated | 2-05 | 4 | 0 | del13q |
| CLL-8 | M | 34 | A | Mutated | 3-72 | 0 | 0 | del13q, del14q |
| CLL-9 | F | 39 | B | Mutated | 4-34 | 19 | 1 | del11q |
| CLL-10 | M | 58 | A | Mutated | 4-34 | 0 | 3 | Negative |
| CLL-11 | F | 58 | B | Unmutated | 3-11 | 81 | 21 | del13q |
| CLL-12 | M | 60 | B | Mutated | 5-51 | 9 | 1 | Negative |
| CLL-13 | F | 44 | A | Unmutated | 3-09 | 0 | 10 | +12 |
| CLL-14 | F | 57 | A | Mutated | 3-30 | 0 | 2 | del13q |
| CLL-15 | F | 45 | A | Mutated | 4-34 | 3 | 0 | Negative |
| CLL-16 | F | 56 | B | Mutated | 2-70 | 10 | 0 | del14q |
| CLL-17 | F | 51 | A | Mutated | 3-21 | 1 | 0 | del13q |
| CLL-18 | M | 84 | A | Unmutated | 4-39 | 77 | 0 | NE |
| CLL-19 | M | 52 | B | Unmutated | 1-69 | 0 | 2 | del11q, +12 |
| CLL-20 | M | 30 | B | Unmutated | 4-34 | 32 | 78 | del13q, del6q |
| CLL patient label . | Sex . | Age at study, y . | Binet stage . | IgVH status . | IgVH gene . | ZAP-70, % . | CD38, % . | FISH analysis . |
|---|---|---|---|---|---|---|---|---|
| CLL-1 | F | 59 | B | Unmutated | 3-33 | 90 | 3 | Negative |
| CLL-2 | M | 59 | A | Unmutated | 1-69 | 65 | 76 | del13q, del11q |
| CLL-3 | M | 45 | A | Unmutated | 3-09 | 74 | 0 | NE |
| CLL-4 | M | 49 | B | Unmutated | 1-69 | 76 | 1 | del11q |
| CLL-5 | M | 59 | B | Unmutated | 3-73 | 10 | 8 | del13q, del14q, del6q |
| CLL-6 | F | 45 | A | Mutated | 4-34 | 0 | 1 | del13q |
| CLL-7 | F | 41 | B | Mutated | 2-05 | 4 | 0 | del13q |
| CLL-8 | M | 34 | A | Mutated | 3-72 | 0 | 0 | del13q, del14q |
| CLL-9 | F | 39 | B | Mutated | 4-34 | 19 | 1 | del11q |
| CLL-10 | M | 58 | A | Mutated | 4-34 | 0 | 3 | Negative |
| CLL-11 | F | 58 | B | Unmutated | 3-11 | 81 | 21 | del13q |
| CLL-12 | M | 60 | B | Mutated | 5-51 | 9 | 1 | Negative |
| CLL-13 | F | 44 | A | Unmutated | 3-09 | 0 | 10 | +12 |
| CLL-14 | F | 57 | A | Mutated | 3-30 | 0 | 2 | del13q |
| CLL-15 | F | 45 | A | Mutated | 4-34 | 3 | 0 | Negative |
| CLL-16 | F | 56 | B | Mutated | 2-70 | 10 | 0 | del14q |
| CLL-17 | F | 51 | A | Mutated | 3-21 | 1 | 0 | del13q |
| CLL-18 | M | 84 | A | Unmutated | 4-39 | 77 | 0 | NE |
| CLL-19 | M | 52 | B | Unmutated | 1-69 | 0 | 2 | del11q, +12 |
| CLL-20 | M | 30 | B | Unmutated | 4-34 | 32 | 78 | del13q, del6q |
NE indicates not evaluated.